Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises BioGaia and its subsidiary Infant Bacterial Therapeutics in connection with a share distribution and separate listing
Mandate

Vinge advises BioGaia and its subsidiary Infant Bacterial Therapeutics in connection with a share distribution and separate listing

February 15, 2016

Vinge advises BioGaia AB (publ) and its subsidiary Infant Bacterial Therapeutics AB (publ) ("IBT") in connection with the proposed distribution of BioGaia’s shares in IBT to the shareholders of BioGaia. In connection with the distribution, IBT will apply for listing of the company's series B shares on Nasdaq First North. IBT is developing a drug (IBP-9414) against necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.

Vinge's team consists of Erik Sjöman, Dain Hård Nevonen, Ludvig Frithiof and Joel Wahlberg. Tora Hansjons advises on tax matters.

Related

Vinge has advised Nordion Energi AB in connection with the acquisition of shares in Kalmar Energi

 Nordion Energi acquires E.ON Sverige AB’s entire stake in Kalmar Energi and in connection with the completion of such, divest Kalmar Energi’s electricity retail business to Siljansvik AB (publ).
May 29, 2026

Vinge advises Latour on the sale of shares in ASSA ABLOY and Securitas, amounting to SEK 2.5 billion in each company

 Vinge has advised Investmentaktiebolaget Latour (publ) in connection with the sale of parts of its shareholdings in ASSA ABLOY and Securitas for a total value of SEK 5 billion.
May 27, 2026

Vinge advises Hybridge Group on the acquisition of NESC

 Hybridge Group and the consultancy firm NESC are merging. Through the merger, Hybridge Group is strengthening its offering in the field of prefabricated structural solutions.
May 27, 2026